Two human monoclonal antibodies that react with membrane antigens associated with human melanoma have been produced in our laboratory. The chemical nature of the antigens was identified as the gangliosides GD2 and GM2, respectively. After laboratory and experimental animal studies of these antibodies, we recently initiated a human therapy trial. Eight patients with subcutaneous or intradermal metastatic melanoma received intra-tumor injections of antibody to GD2. Remarkable regression was observed in some of these patients, without noticeable side effects. To the best of our knowledge, we are the only group successfully producing human monoclonal antibodies to tumor antigens for use in clinical therapy trials. In this application, we will continue the study of intra-tumor injection of human monoclonal antibody, in order to define its anti-tumor effect in cancer patients. The study will examine a new treatment of cutaneous metastatic melanoma as well. Systemic injection of antibody for the treatment of hematogenous and lymphatic metastases will be performed when large-scale production of human monoclonal antibodies is accomplished as proposed in this application. The other arm of this proposal includes the generation of three additional antibodies to melanoma-associated antigens that have been identified and characterized in our laboratory. Preparation of several human monoclonal antibodies, each having a different specificity, is clinically important for two reasons: (1) antigenic expression on tumor cells in heterogeneous, and (2) a single type of surface antigen may not be sufficient for targeting by human monoclonal antibodies for immune cytolysis. We will investigate the potential of individual human monoclonal antibodies as well as a combination of multiple types of human monoclonal antibodies for the treatment of human cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA042396-04
Application #
3183661
Study Section
Experimental Therapeutics Subcommittee 2 (ET)
Project Start
1986-06-01
Project End
1991-05-31
Budget Start
1989-06-01
Budget End
1990-05-31
Support Year
4
Fiscal Year
1989
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Type
Schools of Medicine
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Kanda, S; Cochran, A J; Lee, W R et al. (1992) Variations in the ganglioside profile of uveal melanoma correlate with cytologic heterogeneity. Int J Cancer 52:682-7
Hastings, A; Morrison, S L; Kanda, S et al. (1992) Production and characterization of a murine/human chimeric anti-idiotype antibody that mimics ganglioside. Cancer Res 52:1681-6
Kunitomo, K; Irie, R F; Kern, D H (1992) Modulation of ganglioside expression in human melanoma cell lines;increased resistance to chemo- and radiation treatment. Tokushima J Exp Med 39:55-62
Hoon, D S; Okun, E; Banez, M et al. (1991) Interleukin 4 alone and with gamma-interferon or alpha-tumor necrosis factor inhibits cell growth and modulates cell surface antigens on human renal cell carcinomas. Cancer Res 51:5687-93
Kono, K; Tsuchida, T; Kern, D H et al. (1990) Ganglioside composition of human melanoma and response to antitumor treatment. Cancer Invest 8:161-7
Yamamoto, S; Yamamoto, T; Saxton, R E et al. (1990) Anti-idiotype monoclonal antibody carrying the internal image of ganglioside GM3. J Natl Cancer Inst 82:1757-60
Saito, H; Wen, D R; Yamamoto, S et al. (1990) Murine monoclonal anti-idiotype antibody (alpha) as a probe to detect human monoclonal antibody bound to human tumor tissues. J Immunol Methods 134:121-8
Ravindranath, M H; Morton, D L; Irie, R F (1989) An epitope common to gangliosides O-acetyl-GD3 and GD3 recognized by antibodies in melanoma patients after active specific immunotherapy. Cancer Res 49:3891-7
Irie, R F; Matsuki, T; Morton, D L (1989) Human monoclonal antibody to ganglioside GM2 for melanoma treatment. Lancet 1:786-7
Ravindranaths, M H; Paulson, J C; Irie, R F (1988) Human melanoma antigen O-acetylated ganglioside GD3 is recognized by Cancer antennarius lectin. J Biol Chem 263:2079-86

Showing the most recent 10 out of 14 publications